Cargando…

In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library

Neutralizing antibodies targeting the receptor-binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and/or treat COVID-19. However, as SARS-CoV-2 has evolved into new variants, most of the neutralizing antibodies authorized by the US FDA and/or EMA to treat COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: González-González, Edith, Carballo-Uicab, Gregorio, Salinas-Trujano, Juana, Cortés-Paniagua, María I., Vázquez-Leyva, Said, Vallejo-Castillo, Luis, Mendoza-Salazar, Ivette, Gómez-Castellano, Keyla, Pérez-Tapia, Sonia M., Almagro, Juan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496002/
https://www.ncbi.nlm.nih.gov/pubmed/36134953
http://dx.doi.org/10.3390/antib11030057
_version_ 1784794161081221120
author González-González, Edith
Carballo-Uicab, Gregorio
Salinas-Trujano, Juana
Cortés-Paniagua, María I.
Vázquez-Leyva, Said
Vallejo-Castillo, Luis
Mendoza-Salazar, Ivette
Gómez-Castellano, Keyla
Pérez-Tapia, Sonia M.
Almagro, Juan C.
author_facet González-González, Edith
Carballo-Uicab, Gregorio
Salinas-Trujano, Juana
Cortés-Paniagua, María I.
Vázquez-Leyva, Said
Vallejo-Castillo, Luis
Mendoza-Salazar, Ivette
Gómez-Castellano, Keyla
Pérez-Tapia, Sonia M.
Almagro, Juan C.
author_sort González-González, Edith
collection PubMed
description Neutralizing antibodies targeting the receptor-binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and/or treat COVID-19. However, as SARS-CoV-2 has evolved into new variants, most of the neutralizing antibodies authorized by the US FDA and/or EMA to treat COVID-19 have shown reduced efficacy or have failed to neutralize the variants of concern (VOCs), particularly B.1.1.529 (Omicron). Previously, we reported the discovery and characterization of antibodies with high affinity for SARS-CoV-2 RBD Wuhan (WT), B.1.617.2 (Delta), and B.1.1.529 (Omicron) strains. One of the antibodies, called IgG-A7, also blocked the interaction of human angiotensin-converting enzyme 2 (hACE2) with the RBDs of the three strains, suggesting it may be a broadly SARS-CoV-2 neutralizing antibody. Herein, we show that IgG-A7 efficiently neutralizes all the three SARS-CoV-2 strains in plaque reduction neutralization tests (PRNTs). In addition, we demonstrate that IgG-A7 fully protects K18-hACE2 transgenic mice infected with SARS-CoV-2 WT. Taken together, our findings indicate that IgG-A7 could be a suitable candidate for development of antibody-based drugs to treat and/or prevent SARS-CoV-2 VOCs infection.
format Online
Article
Text
id pubmed-9496002
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94960022022-09-23 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library González-González, Edith Carballo-Uicab, Gregorio Salinas-Trujano, Juana Cortés-Paniagua, María I. Vázquez-Leyva, Said Vallejo-Castillo, Luis Mendoza-Salazar, Ivette Gómez-Castellano, Keyla Pérez-Tapia, Sonia M. Almagro, Juan C. Antibodies (Basel) Article Neutralizing antibodies targeting the receptor-binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and/or treat COVID-19. However, as SARS-CoV-2 has evolved into new variants, most of the neutralizing antibodies authorized by the US FDA and/or EMA to treat COVID-19 have shown reduced efficacy or have failed to neutralize the variants of concern (VOCs), particularly B.1.1.529 (Omicron). Previously, we reported the discovery and characterization of antibodies with high affinity for SARS-CoV-2 RBD Wuhan (WT), B.1.617.2 (Delta), and B.1.1.529 (Omicron) strains. One of the antibodies, called IgG-A7, also blocked the interaction of human angiotensin-converting enzyme 2 (hACE2) with the RBDs of the three strains, suggesting it may be a broadly SARS-CoV-2 neutralizing antibody. Herein, we show that IgG-A7 efficiently neutralizes all the three SARS-CoV-2 strains in plaque reduction neutralization tests (PRNTs). In addition, we demonstrate that IgG-A7 fully protects K18-hACE2 transgenic mice infected with SARS-CoV-2 WT. Taken together, our findings indicate that IgG-A7 could be a suitable candidate for development of antibody-based drugs to treat and/or prevent SARS-CoV-2 VOCs infection. MDPI 2022-09-06 /pmc/articles/PMC9496002/ /pubmed/36134953 http://dx.doi.org/10.3390/antib11030057 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
González-González, Edith
Carballo-Uicab, Gregorio
Salinas-Trujano, Juana
Cortés-Paniagua, María I.
Vázquez-Leyva, Said
Vallejo-Castillo, Luis
Mendoza-Salazar, Ivette
Gómez-Castellano, Keyla
Pérez-Tapia, Sonia M.
Almagro, Juan C.
In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library
title In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library
title_full In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library
title_fullStr In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library
title_full_unstemmed In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library
title_short In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library
title_sort in vitro and in vivo characterization of a broadly neutralizing anti-sars-cov-2 antibody isolated from a semi-immune phage display library
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496002/
https://www.ncbi.nlm.nih.gov/pubmed/36134953
http://dx.doi.org/10.3390/antib11030057
work_keys_str_mv AT gonzalezgonzalezedith invitroandinvivocharacterizationofabroadlyneutralizingantisarscov2antibodyisolatedfromasemiimmunephagedisplaylibrary
AT carballouicabgregorio invitroandinvivocharacterizationofabroadlyneutralizingantisarscov2antibodyisolatedfromasemiimmunephagedisplaylibrary
AT salinastrujanojuana invitroandinvivocharacterizationofabroadlyneutralizingantisarscov2antibodyisolatedfromasemiimmunephagedisplaylibrary
AT cortespaniaguamariai invitroandinvivocharacterizationofabroadlyneutralizingantisarscov2antibodyisolatedfromasemiimmunephagedisplaylibrary
AT vazquezleyvasaid invitroandinvivocharacterizationofabroadlyneutralizingantisarscov2antibodyisolatedfromasemiimmunephagedisplaylibrary
AT vallejocastilloluis invitroandinvivocharacterizationofabroadlyneutralizingantisarscov2antibodyisolatedfromasemiimmunephagedisplaylibrary
AT mendozasalazarivette invitroandinvivocharacterizationofabroadlyneutralizingantisarscov2antibodyisolatedfromasemiimmunephagedisplaylibrary
AT gomezcastellanokeyla invitroandinvivocharacterizationofabroadlyneutralizingantisarscov2antibodyisolatedfromasemiimmunephagedisplaylibrary
AT pereztapiasoniam invitroandinvivocharacterizationofabroadlyneutralizingantisarscov2antibodyisolatedfromasemiimmunephagedisplaylibrary
AT almagrojuanc invitroandinvivocharacterizationofabroadlyneutralizingantisarscov2antibodyisolatedfromasemiimmunephagedisplaylibrary